Rachel Egler, MD
- Chair, Institutional Review Board, UH Seidman Cancer Center
- Director, Outpatient Services, UH Cleveland Medical Center
- Director, Pediatric Hematology and Oncology, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
- Angie Fowler Chair in Adolescent & Young Adult Cancer Research, UH Rainbow Babies & Children's Hospital
- Specialty: Pediatric Hematology and Oncology
-
Location:UH Rainbow Babies & Children's Hospital
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-844-1443
Biography: Rachel Egler, MD
Expertise
Certifications & Memberships
- Pediatric Hematology-Oncology - American Board of Pediatrics
Education
Fellowship | Pediatric Hematology/Oncology
Pediatric Hematology/Oncology - Children's Hospital Of Pittsburgh Of Upmc (2002 - 2005)
Residency | Pediatrics
Pediatrics - Cleveland Clinic (1999 - 2002)
Other Education
Baylor College Of Medicine (2009)
Medical Education
Albany Medical College (1999)
Undergraduate
Northwestern University (1992)
About
Rachel Egler, MD, is a pediatric cancer specialist (hematology and oncology) and Director of Outpatient Services for the Angie Fowler Adolescent and Young Adult Cancer Institute in the Division of Hematology and Oncology at University Hospitals Rainbow Babies & Children's Hospital. She is Assistant Professor, Pediatrics, Case Western Reserve University School of Medicine.
Dr. Egler is board certified in pediatrics and hematology-oncology, and her special interest is pediatric oncology. She joined the UH Rainbow Babies & Children's Hospital staff in 2008 from Texas Children’s Cancer Center- Baylor College of Medicine, Houston, Texas.
She graduated from Northwestern University, Evanston, Ill., and completed a post-baccalaureate year at the University of Pennsylvania, Philadelphia, Pa. She earned her doctorate in medicine from Albany Medical College, Albany, N.Y. She served a residency in pediatrics at Cleveland Clinic, Cleveland, Ohio, and a fellowship in pediatric hematology and oncology at Children's Hospital of Pittsburgh, Pittsburgh, Pa. While attending at Texas Children’s Cancer Center, she obtained a Master of Science in Clinical Research from Baylor College of Medicine.
Dr. Egler’s clinical research interest is in the treatment of pediatric solid tumors, including neuroblastoma, sarcomas, germ cell tumors and other rare pediatric cancers. She currently is part of a Children’s Oncology Group clinical trial committee on the treatment of children with germ cell tumors, a unique type of tumor most common in infants and teens ages 15 – 19. She is Primary Investigator on an outcomes study of children with sacrococcygeal teratomas, a type of germ cell tumor. She has participated in research presented at prestigious international and national medical meetings, including the International Society of Paediatric Oncology and the American Society of Pediatric Hematology.
Dr. Egler has published 10 articles since 2005 in peer-reviewed scientific and medical journals, primarily on the molecular basis for pediatric cancers, and she is a reviewer for several journals, including Cancer Epidemiology, International Journal of Cancer and Pediatrics.
She is a member of the American Society of Clinical Oncology, Children’s Oncology Group, American Society of Pediatric Hematology and Oncology and the Case Comprehensive Cancer Center.
In addition to her clinical work, Dr. Egler chairs the University Hospitals Cancer Institutional Review Board. She is also the Associate Director of the Pediatric Hematology-Oncology Fellowship.
Honors and Recognition
Top Doctors, Castle Connolly, 2012-2014
Annual Pediatric Hematology Oncology Fellows’ Teaching Award, UH Rainbow Babies & Children’s Hospital, 2013
Top Oncologist, US News & World Report, 2011, 2012
Research Interests
Germ cell tumors
Featured Videos
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Rachel Egler did not disclose any Outside Relationships with Industry.